Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children

Pediatric Infectious Disease Journal

Volumn 32, Issue 8, 2013, Pages 851-855

  Technau, Karl Günter ^a   Lazarus, Erica ^b   Kuhn, Louise ^c   Abrams, Elaine J ^d   Sorour, Gillian ^a   Strehlau, Renate ^a   Reubenson, Gary ^a   Davies, Mary Ann ^e   Coovadia, Ashraf ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c Vagelos College of Physicians and Surgeons   (United States)

^d Department of Medicine   (United States)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

abacavir; children; first line antiretroviral therapy; HIV

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE PLUS STAVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR; ZIDOVUDINE;

ARTICLE; CHILD; CONTROLLED STUDY; DEMOGRAPHY; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SOUTH AFRICA; SYRUP; TABLET FORMULATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIROLOGY; VIRUS LOAD; VIRUS STRAIN;

ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84880620087     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31828c3738     Document Type: Article

References (22)

1. World Health Organization, UNAIDS, UNICEF. Global HIV/AIDS Response: Epidemic Update and Health Sector Progress Towards Universal Access: Progress Report 2011. Geneva: World Health Organization; 2011.
2. Babiker A, Castronee Green H, Compagnucci A, et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIVinfected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis. 2011;11:273-283.
3. Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA. 2010;304:1082-1090.
4. Kuhn L, Coovadia A, Strehlau R, et al. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012;12:521-530.
5. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access-2010 revision. 2010 rev. ed. Geneva: World Health Organization; 2010.
6. National Department of Health. Guidelines for the Management of HIV in Children-2nd Edition 2010. 2010 rev. ed. Pretoria: National Department of Health; 2010.
7. Green H, Gibb DM, Walker AS, et al.; Paediatric European Network for the Treatment of AIDS (PENTA). Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS. 2007;21:947-955.
8. Welch S, Sharland M, Lyall EG, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med. 2009;10:591-613.
9. Meyers TM, Yotebieng M, Kuhn L, et al. Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa. Pediatr Infect Dis J. 2011;30:974-979.
10. Davies MA, Moultrie H, Eley B, et al.; International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration. Virologic failure and second-line antiretroviral therapy in children in South Africa-the IeDEA Southern Africa collaboration. J Acquir Immune Defic Syndr. 2011;56:270-278.
11. Zanoni BC, Phungula T, Zanoni HM, et al. Impact of tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating HAART. AIDS. 2011;25:49-55.
12. Davies MA, Boulle A, Fakir T, et al. Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study. BMC Pediatr. 2008;8:34.
13. Johnson VA, Calvez V, Günthard HF, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2011;19:156-164.
14. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med. 2011;8:e1000430.
15. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavirboosted lopinavir for HIV-infected children. N Engl J Med. 2012;366:2380-2389.
16. Waters LJ, Moyle G, Bonora S, et al. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir Ther (Lond). 2007;12:825-830.
17. Gibb DM, Walker AS, Kaye S, et al. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial). Antivir Ther (Lond). 2002;7:293-303.
18. Sax PE, Tierney C, Collier AC, et al.; AIDS Clinical Trials Group Study A5202 Team. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204:1191-1201.
19. Hill A, Sawyer W. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. HIV Med. 2009;10:527-535.
20. Staszewski S, Keiser P, Montaner J, et al.; CNAAB3005 International Study Team. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA. 2001;285:1155-1163.
21. Kumar PN, Salvato P, Lamarca A, et al. A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ES100327, the ACTION Study). AIDS Res Ther. 2009;6:3.
22. Technau K, Kalk E, Sherman GG, et al. Influx of infants to HIV treatment services in the context of improvements in PMTCT. In: 15th International Workshop on HIV Observational Databases; March 24-26, 2011. Prague, Czech Republic; 2011.